Uncategorized
How South Carolina Became the Southeast’s Fastest Growing Biotech Hub
Sponsored content brought to you by
South Carolina just landed a $1.5 billion investment and more than 1,200 jobs, as Octapharma Plasma relocates its U.S. headquarters from Charlotte to Rock Hill and builds its first U.S. manufacturing facility there. Leaving an established base for somewhere newer is a bet, and Octapharma isn’t alone. It’s the latest data point in a five-year run that has landed South Carolina on GEN’s list of Next10 Emerging Biotech Hubs, ecosystems built for established manufacturers and growth-stage companies alike, not a copy of hubs elsewhere.
Manufacturers are choosing South Carolina to expand, drawn by talent, a business-friendly climate, and quality of life. In Charleston, SHL Medical’s $220 million, 300-job drug-delivery facility, producing autoinjectors and pen injectors for pharmaceutical partners worldwide, is one recent example. Suppliers are also increasing their investments. Charles River Laboratories has expanded its Charleston County operations with advanced cleanroom and automation capabilities, helping ensure biologics and vaccines reach patients faster and more safely.
In Columbia, the Ritedose Corporation, a leading Blow-Fill-Seal CDMO for generic pharmaceuticals, is on track to produce over two billion doses per year with its new 225,000-square-foot distribution center, part of an $81 million investment that has created 100 additional jobs.
The pipeline behind that scale starts at South Carolina’s research universities. Clemson University is advancing precision medicine and bioengineering through its Institute for Human Genetics, which excels at disease modeling, genomics, and drug discovery; and its Biomedical Engineering Innovation Campus, which brings together world-renowned bioengineers, Prisma Health clinicians, and innovative startups in a 31,000-square-foot facility.
As the state’s only NCI-Designated Cancer Center, the Medical University of South Carolina attracts nationally-recognized researchers and federal funding. With plans to double its research faculty and build a new facility for its cellular therapy program, the university ranks in the top 15% most innovative institutions nationwide on the CURE Innovation Index. And the University of South Carolina opened a 65,000-square-foot Brain Health Center, part of a $350 million investment bringing clinical care, imaging, and research together for patients with Alzheimer’s disease and related dementias.
That talent pipeline is also pulling in companies that didn’t start here. GNQ Insilico, a techbio company using artificial intelligence, quantum computing, and digital twin technology to predict how patients respond to treatment, moved its U.S. headquarters and lab from Silicon Valley to Greenville. “We want Greenville to know that we are building something enduring here,” said GNQ founder and CEO Rehan Huda. This is not a temporary outpost, but a long-term bet on the state’s talent, collaboration, and business climate.
People often ask why MassBio, based in the country’s most established life sciences hub, chose to partner with South Carolina at all. The answer traces back to its visionary leadership, who saw this ecosystem taking shape years before most people noticed and wanted their resources to give good science a real chance beyond Boston. That’s the thinking behind Drive, the accelerator powered by SCbio and Massbio. Drive has connected emerging life sciences companies with mentors from partners such as Eli Lilly and Company and Labcorp. Since launching in 2022, it has supported 70 early-stage companies that have raised $137 million and created nearly 100 jobs.
And it’s a pattern that holds: companies that locate here tend to expand here, and it’s exactly why South Carolina made this list. PAI Pharma, a Greenville-based leader in oral liquid medications, has invested millions in expansions since arriving decades ago; AmbioPharm has grown its Aiken County peptide operations too.
A hub doesn’t stay “emerging” forever. The window to get in early is now. Join us in South Carolina, where we’re building the life and the science that propel the future.

Why South Carolina?
The post How South Carolina Became the Southeast’s Fastest Growing Biotech Hub appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read
